| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/24/2003 | WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 04/24/2003 | WO2003033632A1 Cholesterol lowering structured lipids with omega 6 pufa |
| 04/24/2003 | WO2003033528A1 Cyclic peptides as g-protein-coupled receptor antagonists |
| 04/24/2003 | WO2003033524A2 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | WO2003033518A1 Steroidal compounds for inhibiting steroid sulphatase |
| 04/24/2003 | WO2003033514A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 04/24/2003 | WO2003033507A1 Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same |
| 04/24/2003 | WO2003033506A1 Aminoborane acid derivative and proteasome inhibitory drug containing the same |
| 04/24/2003 | WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | WO2003033501A1 Himbacine analogues as thrombin receptor antagonists |
| 04/24/2003 | WO2003033499A2 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 04/24/2003 | WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors |
| 04/24/2003 | WO2003033491A1 Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition |
| 04/24/2003 | WO2003033487A1 Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 04/24/2003 | WO2003033486A1 Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
| 04/24/2003 | WO2003033484A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 04/24/2003 | WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them |
| 04/24/2003 | WO2003033480A1 Lactam derivatives as antagonists for human 11cby receptors |
| 04/24/2003 | WO2003033478A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
| 04/24/2003 | WO2003033476A1 Pyrimidinones as melanin concentrating hormone receptor 1 |
| 04/24/2003 | WO2003033472A1 Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors |
| 04/24/2003 | WO2003033471A1 Novel pyridone derivative and remedial agent for circulatory disease containing the same |
| 04/24/2003 | WO2003033470A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 04/24/2003 | WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 04/24/2003 | WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS |
| 04/24/2003 | WO2003033453A1 Dicarboxylic acid derivatives, their preparation and therapeutical use |
| 04/24/2003 | WO2003033445A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 04/24/2003 | WO2003033417A1 Titanium-group metal containing high-performance water, and its producing method and apparatus |
| 04/24/2003 | WO2003033029A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | WO2003033023A1 Drugs ameliorating hypo-hdl cholesterolemia |
| 04/24/2003 | WO2003033017A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 04/24/2003 | WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases |
| 04/24/2003 | WO2003033004A1 Agents for treating inflammatory bowel diseases |
| 04/24/2003 | WO2003033003A1 Agent controlling the production of osteoclast formation regulator and method of screening substance capable of controlling the production of osteoclast formation regulator |
| 04/24/2003 | WO2003033002A1 Intracellular calcium concentration increase inhibitors |
| 04/24/2003 | WO2003033001A1 Combinations comprising cox-2 inhibitors and aspirin |
| 04/24/2003 | WO2003033000A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 04/24/2003 | WO2003032999A1 Alkyne matrix metalloproteinase inhibitors |
| 04/24/2003 | WO2003032997A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
| 04/24/2003 | WO2003032996A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
| 04/24/2003 | WO2003032993A1 Use of phosphorodiesterase iv inhibitors |
| 04/24/2003 | WO2003032988A1 Pharmaceutical composition |
| 04/24/2003 | WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032985A2 Concomitant oral and topical administration of anti - infective agents |
| 04/24/2003 | WO2003032984A1 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| 04/24/2003 | WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents |
| 04/24/2003 | WO2003032981A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032979A1 Malignant cell differentiation inducer compositions and utilization of the same |
| 04/24/2003 | WO2003032972A1 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032968A1 Compositions for lessening oxidative stress |
| 04/24/2003 | WO2003032966A1 Compositions for potentiating glutatthione |
| 04/24/2003 | WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
| 04/24/2003 | WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | WO2003032963A2 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | WO2003032921A2 Treatment of neurodegenerative diseases and cancer of the brain |
| 04/24/2003 | WO2003032920A2 Oligonucleotide modulation of cell adhesion |
| 04/24/2003 | WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases |
| 04/24/2003 | WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | WO2003032905A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 04/24/2003 | WO2003032898A2 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | WO2003032735A1 Remodeling of tissues and organs |
| 04/24/2003 | WO2002102376A8 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT |
| 04/24/2003 | WO2002100437A3 Ophthalmic compositions comprising hyaluronic acid |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002098850A3 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 04/24/2003 | WO2002089841A3 Method of preventing cell death using antibodies to neural thread proteins |
| 04/24/2003 | WO2002088343A3 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) |
| 04/24/2003 | WO2002088180A3 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 04/24/2003 | WO2002076509A3 Preparation for the prophylaxis of restenosis |
| 04/24/2003 | WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002060436A8 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 04/24/2003 | WO2002058690A3 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 04/24/2003 | WO2002053137A3 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 04/24/2003 | WO2002051988A3 Thymic epithelial progenitor cells and uses thereof |
| 04/24/2003 | WO2002045710A9 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002038171A3 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 04/24/2003 | WO2002026825A3 G-protein coupled receptors |
| 04/24/2003 | WO2002024180A3 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 04/24/2003 | WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 04/24/2003 | WO2002014554A3 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 04/24/2003 | WO2001080900A3 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
| 04/24/2003 | US20030079237 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 04/24/2003 | US20030078438 N-heterocyclicamide compounds; used as anticoagulant agent |
| 04/24/2003 | US20030078434 An aromatic sulfonamide compound for treating glomerulonephritis and diabetic nephropathy, having a superior antiproteinuric effect and superior inhibitory activity for type IV collagenase |
| 04/24/2003 | US20030078432 Novel benzotriazoles anti-inflammatory compounds |
| 04/24/2003 | US20030078427 Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| 04/24/2003 | US20030078426 Thiazolidine or oxazolidine compounds useful for preventing or therapeutical agents for various diseases such as diabetes and hyperlipemia |
| 04/24/2003 | US20030078419 For therapy of autoimmune diseases mediated by cathepsin S; for inhibiting the progression of tissue transplant rejection |
| 04/24/2003 | US20030078418 Useful potentiators of beta -lactam antibiotics; therapy |
| 04/24/2003 | US20030078417 For protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents; for therapy of phospholipase mediated injury, injury due to oxidation, and inflammation |